Trials / Completed
CompletedNCT07239102
Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
A Real-World Clinical Retrospective Study of Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Firmonertinib | Firmonertinib any dose, oral |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2025-05-01
- Completion
- 2025-10-01
- First posted
- 2025-11-20
- Last updated
- 2025-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07239102. Inclusion in this directory is not an endorsement.